Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 3, 2014, Pages 945-953

  Boyd, Peter ^a   Major, Ian ^b   Wang, Weiguang ^c   McConville, Christopher ^d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Athletic Rehabilitation Therapy Ireland   (Ireland)

^c UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^d UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Cervical cancer; Controlled release; Disulfiram; Localised delivery; Sustained release; Vaginal ring

Indexed keywords

ANTINEOPLASTIC AGENT; DISULFIRAM; DRUG CARRIER; ETHYLENE VINYL ACETATE COPOLYMER; SILASTIC;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG SCREENING; DRUG STABILITY; FEMALE; GLASS TRANSITION TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LUNG CANCER; MELTING POINT; PROSTATE CANCER; THERMAL ANALYSIS; THERMOSTABILITY; UTERINE CERVIX CANCER; VAGINA RING; FEMALE CONTRACEPTIVE DEVICE; METABOLISM; SYNTHESIS; TREATMENT OUTCOME; TRENDS; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; CONTRACEPTIVE DEVICES, FEMALE; DISULFIRAM; DRUG CARRIERS; FEMALE; HUMANS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84912127124     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.08.002     Document Type: Article

References (53)

1. A.C. de Freitas, A.P. Gurgel, B.S. Chagas, E.C. Coimbra, and C.M. do Amaral Susceptibility to cervical cancer: an overview Gynecol. Oncol. 126 2012 304 311
2. E.I. Franco, N.F. Schlecht, and D. Saslow The epidemiology of cervical cancer Cancer J. 9 2009 348 359
3. I.C. Scarinci, F.A. Garcia, E. Kobetz, E.E. Partridge, H.M. Brandt, and M.C. Bell Cervical cancer prevention: new tools and old barriers Cancer 116 2010 2531 2542
4. M. Schiffma, P.E. Castle, J. Jeronimo, A.C. Rodriguez, and S. Wacholder Human papillomavirus and cervical cancer Lancet 370 2007 890 907
5. L.N. Chien, E.K. Adams, and L.C. Flowers Treating cervical cancer: breast and cervical cancer prevention and treatment act patients Am. J. Obstet. Gynecol. 204 2011 533
6. J.B. Wolinsky, Y.L. Colson, and M.W. Grinstaff Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers J. Control. Release 159 2012 14 26
7. D. Friend Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections Drug Deliv. Transl. Res. 1 2011 185 193
8. A. Loxley, M. Mitchnick, O. Okoh, J. McConnell, L. Goldman, C. Morgan, M. Clark, and D.R. Friend Ethylene vinyl acetate intravaginal rings for the simultaneous delivery of the antiretroviral UC781 and contraceptive levonorgestrel Drug Deliv. Transl. Res. 1 2011 247 255
9. R.K. Malcolm, A.D. Woolfson, C.F. Toner, R.J. Morrow, and S.D. McCullagh Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings J. Antimicrob. Chemother. 56 2005 954 956
10. C. McConville, I. Major, D.R. Friend, M.R. Clark, and R.M. Malcolm Development of a UC781 releasing poly ethylene vinyl acetate vaginal ring Drug Deliv. Transl. Res. 2 2012 489 497
11. C. McConville, D.R. Friend, M.R. Clark, and K. Malcolm Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet containing a single excipient J. Pharm. Sci. 102 2013 1859 1866
12. R.M. Malcolm, C.J. Forbes, L. Geer, R.S. Veazey, L. Goldman, P.J. Klasse, and J.P. Moore Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques J. Antimicrob. Chemother. 68 2013 678 683
13. A.Q. Karim, S.S.A. Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, A.B.M. Kharsany, S. Sibeko, K.P. Mlisana, Z. Omar, T.N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, and D. Taylor Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 2010 1168 1174
14. R.K. Malcolm, S.D. McCullagh, R.J. Morrow, and A.D. Woolfson Vagina and uterus as drug-absorbing organs E. Touitou, B.W. Barry, Enhancement in Drug Delivery seventh ed. 2006 CRC Press Baton Rouge 395 431
15. A.D. Woolfson, R.K. Malcolm, and R. Gallagher Drug delivery by the intravaginal route Crit. Rev. Ther. Drug Carrier Syst. 17 2000 509 555
16. A.D. Woolfson A bioadhesive patch cervical drug delivery system for the administration of 5-fluorouracil to cervical tissue J. Control. Release 35 1995 49 58
17. V. Graham, E.S. Surwit, S. Weiner, and F.L. Meyskens Phase II trial of betaall-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap West. J. Med. 145 1986 192 195
18. P. Kirwan, and N.J. Naftalin Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia Br. J. Obstet. Gynaecol. 92 1985 287 291
19. V. Keskar, P.S. Mohanty, E.J. Gemeinhart, and R.A. Gemeinhart Cervical cancer treatment with a locally insertable controlled release delivery system J. Control. Release 115 2006 280 288
20. L.S. Hodge, L.S. Downs, J.C. Chura, S.G. Thomas, P.S. Callery, A.P. Soisson, P. Kramer, S.S. Wolfe, and T.S. Tracy Localized delivery of chemotherapy to the cervix for radiosensitization Gynecol. Oncol. 127 2012 121 125
21. A.D. Woolfson, G.R.E. Elliott, C.A. Gilligan, and C.M. Passmore Design of an intravaginal ring for the controlled delivery of 17beta-estradiol as its 3-acetate ester J. Control. Release 61 1999 319 328
22. R.K. Malcolm Vaginal rings for controlled release drug delivery M.J. Rathbone, J. Hadgraft, M.S. Roberts, M.E. Lane, Modified Release Drug Delivery Technology second ed. 2008 Informa Healthcare New York 499 510
23. C. Brucker, U. Karck, and E. Merkle Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing®: results of clinical experience in Germany Eur. J. Contracept. Reprod. Health Care 13 2008 31 38
24. A.D. Woolfson, R.K. Malcolm, and R.J. Gallagher Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin J. Control. Release 91 2003 465 476
25. H.J. Ahrendt, I. Nisand, C. Bastianelli, M.A. Gomez, K. Gemzell-Danielsson, W. Urdl, B. Karskov, L. Oeyen, J. Bitzer, G. Page, and I. Milsom Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 mg of ethinyl estradiol and 3 mg of drospirenone Contraception 74 2006 451 457
26. S. Chaplin, and T. Peers NuvaRing: new combined hormonal contraceptive device Prescriber 20 1999 17 20
27. L. Henriksson, M. Stjernquist, L. Boquist, I. Cedergren, and I. Selinus A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging Am. J. Obstet. Gynecol. 174 1996 85 92
28. M. Wickström, K. Danielsson, L. Rickardson, J. Gullbo, P. Nygren, A. Isaksson, R. Larsson, and H. Lövborg Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients Biochem. Pharmacol. 73 2006 25 33
29. N.C. Yip, I.S. Fombon, P. Liu, S. Brown, V. Kannappan, and A.L. Armesilla Disulfiram modulated ROS-MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell-like properties Br. J. Cancer 104 2011 1564 1574
30. P. Liu, S. Brown, T. Goktug, P. Channathodiyil, V. Kannappan, and J.P. Hugnot Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells Br. J. Cancer 107 2012 1488 1497
31. D. Chen, Q.C. Cui, H. Yang, and Q.P. Dou Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity Cancer Res. 66 2006 10425 10433
32. K. Iljin, K. Ketola, P. Vainio, P. Halonen, P. Kohonen, and V. Fey High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth Clin. Cancer Res. 15 2009 6070 6078
33. K. Ketola, O. Kallioniemi, and K. Iljin Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells PLoS ONE 7 2012 e51470
34. Y. Minagawa, J. Kigawa, H. Itamochi, Y. Kanamori, M. Shimada, and M. Takahashi Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways Jpn. J. Cancer Res. 90 1999 1373 1379
35. S.S. Brar, C. Grigg, K.S. Wilson, W.D. Holder, D. Dreau, and C. Austin Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease Mol. Cancer Ther. 3 2004 1049 1060
36. P. Dufour, J.M. Lang, C. Giron, B. Duclos, P. Haehnel, and D. Jaeck Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study Biotherapy 6 1993 9 12
37. S. Verma, D.J. Stewart, J.A. Maroun, and R.C. Nair A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram Am. J. Clin. Oncol. 13 1990 119 124
38. D. Cen, R.I. Gonzalez, J.A. Buckmeier, R.S. Kahlon, N.B. Tohidian, and F.L. Meyskens Disulfiram induces apoptosis in human melanoma cells: a redox-related process Mol. Cancer Ther. 1 2002 197 204
39. D. Cen, D. Brayton, B. Shahandeh, F.L. Meyskens, and P.J. Farmer Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells J. Med. Chem. 47 2004 6914 6920
40. D.G. Barceloux Copper J. Toxicol. 37 1999 217 230
41. M.J. Burkitt, H.S. Bishop, L. Milne, S.Y. Tsang, G.J. Provan, C.S. Nobel, S. Orrenius, and A.F. Slater Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species Arch. Biochem. Biophys. 353 1998 73 84
42. C.I. Nobel, M. Kimland, B. Lind, S. Orrenius, and A.F. Slater Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper J. Biol. Chem. 270 1995 26202 26208
43. T. Estey, J. Piatigorsky, N. Lassen, and V. Vasiliou ALDH3A1: a corneal crystallin with diverse functions Exp. Eye Res. 84 2007 3 12
44. H. Nakano, A. Nakajima, S. Sakon-Komazawa, J.H. Piao, X. Xue, and K. Okumura Reactive oxygen species mediate crosstalk between NF-kappaB and JNK Cell Death Differ. 13 2006 730 737
45. W. Wang, H.L. McLeod, and J. Cassidy Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines Int. J. Cancer 104 2003 504 511
46. X. Guo, B. Xu, S. Pandey, E. Goessl, J. Brown, A.L. Armesilla, J.L. Darling, and W. Wang Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines Cancer Lett. 290 2009 104 113
47. C. McConville, G. Andrews, T. Laverty, D. Woolfson, and K. Malcolm Rheological evaluation of the isothermal cure characteristics of medical grade silicone elastomers J. Appl. Polym. Sci. 116 2010 2320 2327
48. T. Sandberg, J. Rosenholm, and M. Hotokka The molecular structure of disulfiram and its complexation with silica. A quantum chemical study J. Mol. Struct.: THEOCHEM 861 2008 57 61
49. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
50. B. Rambali, G. Verreck, L. Baert, and D.L. Massart Itraconazole formulation studies of the melt-extrusion process with mixture design Drug Dev. Ind. Pharm. 29 2003 641 652
51. S. Hülsmann, T. Backensfeld, S. Keitel, and R. Bodmeier Melt extrusion: an alternative method for enhancing the dissolution rate of 17β-estradiol hemihydrates Eur. J. Pharm. Biopharm. 49 2000 237 242
52. B.C. Hancock, and G. Zografi Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1997 1 12
53. A. Loxley, M. Mitchnick, O. Okoh, J. McConnell, L. Goldman, and C. Morgan Ethylene vinyl acetate intravaginal rings for the simultaneous delivery of the antiretroviral UC781 and contraceptive levonorgestrel Drug Deliv. Transl. Res. 1 2011 247 255